PARD3B and prostate carcinoma: Also, cancer cells may be targeted by the CRISPR-Cas9 system, with knockouts of Par3L, Src-1, and GPRC6A ameliorating colorectal, breast, and prostate cancer respectively, resulting in increased sensitivity to chemotherapeutics, lower proliferation, and higher cancer cell death.